Zobrazeno 1 - 10
of 88
pro vyhledávání: '"John Ouyang"'
Autor:
Ronald D. Perrone, Dorothee Oberdhan, John Ouyang, Daniel G. Bichet, Klemens Budde, Arlene B. Chapman, Berenice Y. Gitomer, Shigeo Horie, Albert C.M. Ong, Vicente E. Torres, A. Neil Turner, Holly Krasa
Publikováno v:
Kidney International Reports, Vol 8, Iss 5, Pp 989-1001 (2023)
Introduction: The course of autosomal dominant polycystic kidney disease (ADPKD) varies greatly among affected individuals, necessitating natural history studies to characterize the determinants and effects of disease progression. Therefore, we condu
Externí odkaz:
https://doaj.org/article/6263893d07674a6789c237002dc53cb4
Autor:
Eiji Higashihara, Hiroshi Fukuhara, John Ouyang, Jennifer Lee, Kikuo Nutahara, Mistuhiro Tanbo, Tsuyoshi Yamaguchi, Satoru Taguchi, Satoru Muto, Shinya Kaname, Isao Miyazaki, Shigeo Horie
Publikováno v:
Kidney International Reports, Vol 5, Iss 9, Pp 1459-1471 (2020)
Introduction: In the Mayo Imaging Classification (MIC) for autosomal dominant polycystic kidney disease (ADPKD), the height-adjusted total kidney volume (HtTKV) growth rate is estimated for classification. Estimated HtTKV slope, termed as eHTKV-α, i
Externí odkaz:
https://doaj.org/article/9c2964d2e0f24a909a9ee0cfff16b82b
Publikováno v:
Urology Case Reports, Vol 36, Iss , Pp 101550- (2021)
A duplicated collecting system is a common congenital anomaly of the urinary tract. However, late symptomatic presentation in adulthood is uncommon. We report the first case of left heminephrectomy, ureterectomy and radical prostatectomy using the da
Externí odkaz:
https://doaj.org/article/0f367d187f2943b789efde2c9e08e3b1
Autor:
Maria V. Irazabal, Jaime D. Blais, Ronald D. Perrone, Ron T. Gansevoort, Arlene B. Chapman, Olivier Devuyst, Eiji Higashihara, Peter C. Harris, Wen Zhou, John Ouyang, Frank S. Czerwiec, Vicente E. Torres
Publikováno v:
Kidney International Reports, Vol 1, Iss 4, Pp 213-220 (2016)
Patients with slowly progressive autosomal dominant polycystic kidney disease (ADPKD) are unlikely to experience outcomes during randomized controlled trials (RCTs). An image classification of ADPKD into typical (diffuse cyst distribution) class 1A t
Externí odkaz:
https://doaj.org/article/3c5812206ddf438eb09cc9d3003af252
Autor:
Vaidehi Krishnan, Florian Schmidt, Zahid Nawaz, Kian Leong Lee, Prasanna Nori Venkatesh, Meera Makheja, Zhu En Chan, Mengge Yu, Nirmala Arul Rayan, Michelle Gek Liang Lim, Alice Cheung, Sudipto Bari, John Ouyang, Owen Rackham, Tuan Zea Tan, William YK Hwang, Charles Chuah, Shyam Prabhakar, Sin Tiong Ong
Publikováno v:
Blood. 140:792-794
Autor:
Xiaolei Zhou, Eric Davenport, John Ouyang, Molly E. Hoke, Diana Garbinsky, Indra Agarwal, Holly B. Krasa, Dorothee Oberdhan
Publikováno v:
Kidney International Reports. 7:1037-1048
In 1- and 3-year randomized trials, tolvaptan slowed kidney function decline in subjects with autosomal dominant polycystic kidney disease (ADPKD) at risk of rapid progression. The 3-year trial also evaluated effects on total kidney volume (TKV); slo
Autor:
Vaidehi Krishnan, Florian Schmidt, Zahid Nawaz, Prasanna Nori Venkatesh, Kian Leong Lee, Xi Ren, Zhu En Chan, Mengge Yu, Meera Makheja, Nirmala Arul Rayan, Michelle Gek Liang Lim, Alice Man Sze Cheung, Sudipto Bari, Wee Joo Chng, Hein Than, John Ouyang, Owen Rackham, Tuan Zea Tan, William Ying Khee Hwang, Charles Chuah, Shyam Prabhakar, S. Tiong Ong
Publikováno v:
Blood.
Primary resistance to tyrosine kinase inhibitors (TKI) is a significant barrier to optimal outcomes in chronic myeloid leukemia, but little is known about the factors contributing to response heterogeneity. Using scRNA-sequencing, we identified eight
Autor:
Judith E Heida, Jennifer H. Lee, Hui Li, Vicente E. Torres, Ron T. Gansevoort, John Ouyang, Ronald D. Perrone, Arlene B. Chapman, Olivier Devuyst
Publikováno v:
Journal of the American Society of Nephrology, 32(7), 1801-1812. AMER SOC NEPHROLOGY
Background: The V2 receptor antagonist tolvaptan is prescribed to patients with autosomal dominant polycystic kidney disease to slow disease progression. Tolvaptan may alter BP via various acute and chronic effects. Methods: To investigate the magnit
Autor:
Satoru Taguchi, Eiji Higashihara, Satoru Muto, Jennifer H. Lee, Shigeo Horie, John Ouyang, Tsuyoshi Yamaguchi, Shinya Kaname, Kikuo Nutahara, Isao Miyazaki, Hiroshi Fukuhara, Mistuhiro Tanbo
Publikováno v:
Kidney International Reports
Kidney International Reports, Vol 5, Iss 9, Pp 1459-1471 (2020)
Kidney International Reports, Vol 5, Iss 9, Pp 1459-1471 (2020)
Introduction In the Mayo Imaging Classification (MIC) for autosomal dominant polycystic kidney disease (ADPKD), the height-adjusted total kidney volume (HtTKV) growth rate is estimated for classification. Estimated HtTKV slope, termed as eHTKV-α, is
Publikováno v:
Clinical Journal of the American Society of Nephrology. 15:643-650
Background and objectives Tolvaptan is approved to slow kidney function decline in adults with autosomal dominant polycystic kidney disease (ADPKD) at risk of rapid progression. Because in vitro studies indicated that the tolvaptan oxobutyric acid me